---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-037546"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2024-08-16T23:59:59+00:00"
generated_at: "2026-05-31T08:49:44.636464+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# X4 Pharmaceuticals receives Nasdaq deficiency notice for minimum bid price rule; 180 days to regain compliance

## Summary
- On Aug 13, 2024, Nasdaq notified X4 that its common stock closing bid price was below $1.00 for 32 consecutive business days.
- Company has until Feb 10, 2025 to regain compliance by closing at $1.00+ for ten consecutive days.
- If not compliant by Feb 10, X4 may be eligible for additional 180-day cure period if it meets other listing standards.
- X4 says it will monitor bid price and consider options including a reverse stock split to cure deficiency.
- There is no immediate delisting; stock continues trading under symbol XFOR on Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001628280-24-037546
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2024-08-16T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828024037546/0001628280-24-037546-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828024037546/xfor-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-037546
- JSON: https://secwatch.observer/filing/0001628280-24-037546.json
- Plain text: https://secwatch.observer/filing/0001628280-24-037546.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.